Serum adenosine deaminase and total immunoglobulin G correlate with markers of immune activation and inversely with CD4 counts in asymptomatic, treatment-naive HIV infection

Journal of Clinical Immunology

Volumn 33, Issue 3, 2013, Pages 605-612

  Ipp, Hayley ^a   Zemlin, Annalise E ^a   Glashoff, Richard H ^a   Van Wyk, Johan ^a   Vanker, Naadira ^a   Reid, Tim ^a   Bekker, Linda Gail ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

HIV; IgG; Immune activation; LBP; SCD14; Serum ADA

Indexed keywords

ADENOSINE DEAMINASE; CD14 ANTIGEN; CD38 ANTIGEN; IMMUNOGLOBULIN G; LIPOPOLYSACCHARIDE BINDING PROTEIN;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROSS-SECTIONAL STUDY; DISEASE COURSE; DISEASE MARKER; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOSTIMULATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SOUTH AFRICA; VIRUS LOAD;

ADENOSINE DEAMINASE; ADULT; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOGLOBULIN G; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; VIRAL LOAD; YOUNG ADULT;

EID: 84879880217     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-012-9832-7     Document Type: Article

References (39)

1. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231-41.
2. Hazenberg MD, Otto SA, van Benthem BHB, Roos MTL, Coutinho RA, Lange JMA, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003; 17:1881-8.
3. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RMM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002;169:3400-6.
4. Dauby N, De Wit S, Delforge M, Necsoi VC, Clumeck N. Characteristics of non-AIDS-defining malignancies in the HAART era: a clinico-epidemiological study. J Int AIDS Soc. 2011;14:16. doi:10.1186/1758-2652-14-16.
5. El-Sadr WM, Lundgren JD, Neaton J, other (the SMART Study Group). CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283-96.
6. Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. INSIGHT SMART Study Group. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780-90.
7. Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 survey. J Clin Infect Dis. 2009;48:633-9.
8. Deeks, Steven G, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. BrMed J. 2009;338: a3172.
9. Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr. 1993;6:904-12.
10. Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4+ cell count, soluble immune activationmarkers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr. 1997;16:83-92.
11. Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced immunodeficiency virus type 1 infection is more closely associated with T-lymphocyte activation then with plasma virus burden or virus chemokine receptor usage. J Infect Dis. 1999;179:859-70.
12. Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003; 187:1534-43.
13. Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365-71.
14. Redd AD, Dabitao D, Bream JH, Charvat B, Laeyendecker O, Kiwanuka N, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A. 2009;106:6718-23.
15. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;80:1584-9.
16. Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010;5(1):PMID:20126452.
17. Eltzschig HK, Faigle M, Knapp S, Karhausen J, Ibla J, Rosenberger P, et al. Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. Blood. 2006;108:1602-10.
18. Cowan MJ, Brady RO, Widder KJ. Elevated erythrocyte adenosine deaminase activity in patients with acquired immunodeficiency syndrome. Proc Natl Acad Sci. 1986;83:1089-91.
19. Gakis C, Calia G, Naitana A, Pirino D, Serru G. Serum adenosine deaminase activity in HIV positive subjects. A hypothesis on the significance of ADA2. Panminerva Med. 1989;31:107-13.
20. Casoli C, Lisa A, Magnani G, Starcich R, Fiaccadori F, Bertazzoni U, et al. Prognostic value of adenosine deaminase compared to other markers for progression to acquired immunodeficiency syndrome among intravenous drug users. J Med Virol. 1995;45:203-10.
21. DeMilito A. B lymphocyte dysfunctions in HIV infection. Curr HIV Res. 2004;2:11-21.
22. De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, et al. Mechanisms of hypergammaglobulinemia and impaired antigen specific humoral immunity in HIV-1 infection. Blood. 2004;103:2180-6.
23. Grogg KL, Miller RF, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60:1365-72.
24. FRAM study Modrich L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAARTera. J Acquir Immune Defic Syndr. 2010;53 (1):102-6.
25. Orsi F, Patrizia M, Carrieri M, Coriat B, Delaporte E, Moatti J-P, et al. Call to action to secure universal access to ART in developing countries. Lancet. 2010;375:1693-4.
26. Sax PE, Baden LR. When to start antiretroviral therapy-ready when you are? N Engl J Med. 2009;360:1897-9.
27. Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011;25:2123-31.
28. Perez-Rodriguez E, Jimenez Castro D. The use of adenosine deaminase and adenosine deaminase isoenzymes in the diagnosis of tuberculous pleuritis. Curr Opin Pulm Med. 2000;6:259-66.
29. Zemlin AE, Burgess LJ, Carstens ME. The diagnostic utility of adenosine deaminase isoenzymes in tuberculous pleural effusions. Int J Tuberc Lung Dis. 2009;13:214-20.
30. Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS One. 2008;3(7):e2788. 10.1371/journal.pone.0002788.
31. Niedzwicki JG, Kouttab NM, Mayer KH, Carpenter CCJ, Parks RE, Abushanab E, et al. Plasma adenosine deaminase2: a marker for human immunodeficiency virus infection. J Acquir Immune Defic. 1991;4:178-82.
32. Rani HS, Madhavi G, Srikanth BMV, Jharna P, Rao URK, Jyothy A. Serum ADA and C-reactive protein in rheumatoid arthritis. Int J Hum Genet. 2006;6(3):195-8.
33. Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010;84(22): 12082-6.
34. Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev. 2001;14:753-77.
35. Amadori A, Gallo P, Zamarchi R, Veronese ML, DeRossi A, Wolf D, et al. IgG oligoclonal bands in sera of HIV-1 infected patients are mainly directed against HIV-1 determinants. AIDS Res Hum Retroviruses. 1990;6:581-6.
36. Konstantinopoulos PA, Dezube BJ, Pantanowitz L, Horowitz GL, Beckwith BA. Protein electrophoresis and immunoglobulin analysis in HIV-infected patients. Am J Clin Pathol. 2007;128:596-603.
37. Van Vuuren M, Zemlin AE, Germishuys JJ. Monoclonal gammopathy and other serum protein electrophoresis patterns in patients with HIV infection in South Africa. Ann Clin Biochem. 2010;47:366-74.
38. Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, et al. Persistent microbial translocation and immune activation in HIV-1-infected South Africans receiving combination antiretroviral therapy. J Infect Dis. 2010;5:723-33.
39. Piconi S, Parisotto S, Rizzardini G, Passerini S, Argenteri RT, Meraviglia BP, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, ART-treated, immunological non responders. Blood. 2011;118:3263-72.